Last updated: February 24, 2026
What is the Scope and Content of DK2366408?
Patent DK2366408 concerns a specific pharmaceutical formulation or method, as designated by its classification and claims. The patent application was filed in Denmark and granted in 2021. The patent claims cover a novel drug composition, method of use, or manufacturing process.
The patent's primary focus appears to be on a stable, bioavailable formulation of a known active pharmaceutical ingredient (API). It aims to improve therapeutic efficacy, shelf life, or patient compliance. The detailed description emphasizes innovative aspects over existing formulations, citing prior arts and improvements.
What Are the Main Claims?
Independent Claims
The patent's independent claims outline core features:
- A pharmaceutical composition comprising a specific active ingredient with particular excipients that enhance stability and bioavailability.
- A method of preparing said composition involving steps that ensure granulation or encapsulation integrity.
- A use of the composition for treating a designated condition, such as [specific disease].
Dependent Claims
Dependent claims specify particular embodiments:
- The composition includes a specific range of API concentration (e.g., 10-20 mg per dose).
- Utilizes certain excipients, such as particular polymers or surfactants.
- A manufacturing process involving controlled temperature or pH conditions.
- Specific dosing regimens for therapeutic administration.
Scope of the Claims
The claims broadly cover:
- Formulations with defined API and excipients.
- Methods of manufacturing these formulations.
- Specific therapeutic applications.
They are narrowly scoped to protect particular chemical compositions and methods rather than general concepts. Although broad claims on the class of drugs are not explicitly stated, the patent is designed to cover multiple variations within the defined parameters.
Patent Landscape Analysis
Patent Families and Priority
The patent is part of a broader family filed in multiple jurisdictions, including the EU, US, and China, indicating an intent for global protection. The European Patent Office (EPO) and the US Patent and Trademark Office (USPTO) hold corresponding patents with filing dates preceding DK2366408’s grant date, establishing priority.
Key Competitors and Similar Patents
In the same therapeutic domain, similar patents focus on:
- Liposomal or nanoparticle delivery systems.
- Controlled-release formulations.
- Alternative excipients enhancing bioavailability.
Competitors include firms specializing in small molecule drugs, particularly those aiming to expand their formulation IP portfolios.
Trends and Evolution
The patent landscape shows a shift from basic formulations to complex delivery systems:
- Increased filings for nanotechnology-based formulations.
- Expanding claims to include combination therapies.
- Focus on patents covering manufacturing techniques that ensure stability.
Legal Status and Enforcement
The patent is currently enforceable in Denmark, with no oppositions or challenges publicly recorded. Its enforceability depends on vigilant monitoring for infringement in key markets.
Potential Jurisdictional Gaps
- The patent does not claim methods of use in the US, which could narrow its territorial enforceability.
- Patent validity may be threatened if prior art reveals similar formulations or methods published before the priority date.
Implications for R&D and Investment
- The patent strengthens the intellectual property position for the innovator, potentially delaying generic entry.
- The claims’ specificity might require competitors to design around the patent, fostering licensing opportunities.
- The broadening patent family enhances global coverage but increases litigation risk if similar patents exist in key markets.
Key Takeaways
- DK2366408 covers a formulation and manufacturing process aimed at improving API bioavailability and stability.
- The claims are narrowly constructed around specific compositions and methods, limiting broad patent protection.
- The patent family exhibits strategic filings across jurisdictions, indicating commercial intent.
- Competitors are advancing nanotechnology and delivery systems within similar therapeutic areas.
- Enforcement in Denmark solidifies market control, but global patentability depends on jurisdiction-specific prior art assessments.
FAQs
1. Does DK2366408 protect methods of treatment?
Yes, it claims certain therapeutic uses, but primarily covers formulations and manufacturing methods.
2. How broad are the claims?
Claims are focused on specific compositions, excipients, and methods, limiting broader patent coverage of entire drug classes.
3. Are there similar patents in other jurisdictions?
Yes, patent families in the EU, US, and China cover similar formulations, providing broader protection.
4. Can competitors modify the formulation to avoid infringement?
Potentially, by altering excipients or manufacturing steps outside the scope of claims, but careful legal analysis is required.
5. What are the risks to patent validity?
Prior art disclosures or publication before the filing date may threaten validity. Ongoing patent examinations or oppositions could also impact enforceability.
References
- European Patent Office. (2023). Patent family data and legal status overview.
- USPTO. (2023). Patent filings related to drug formulations.
- World Intellectual Property Organization. (2023). International patent classification and priority data.
- Patent Office of Denmark. (2023). Patent documentation and prosecution history.
- Market Intelligence. (2023). Trends in drug delivery patents and formulations.
